Prosecution Insights
Last updated: October 04, 2026
Application No. 18/033,911

PHOSPHATE BASED TARGETS

Non-Final OA §103§112
Filed
Apr 26, 2023
Priority
Oct 30, 2020 — GB 2017229.2 +1 more
Examiner
DICKINSON, PAUL W
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITETET I OSLO
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
661 granted / 1047 resolved
+3.1% vs TC avg
Moderate +10% lift
Without
With
+9.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
39 currently pending
Career history
1086
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
42.2%
+2.2% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1047 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Restriction Applicant’s election of 1) wherein the isotopically enriched element or monoisotopic element is Zn in claim 3; 2) wherein the isotope is ⁶⁸Zn in claim 4; 3) wherein the isotopically enriched element or monoisotopic element is Zn in claim 17; and 4) wherein the isotope is ⁶⁸Zn in claim 18 without traverse is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 and 17-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “phosphate based glass target material.” It’s unclear in what way the glass target material is “based” on phosphate, if the glass target material comprises phosphate, if phosphate is used in the process of making the glass target material but is not necessarily present in the material, if the glass target material exhibits properties similar to phosphate but it does not necessarily contain phosphate. For these reasons the term is unclear. Further, it’s unclear what the difference is between a “target material” and a “material,” and how “target” limits the claimed invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-7 and 17-18 are rejected under 35 U.S.C. 103 as being unpatentable over US 6667258 to Quinn in view of Larner (Evaluation of Stable Isotope Tracing for ZnO Nanomaterials New Constraints from High Precision Isotope Analyses and Modeling, Environ. Sci. Technol. 2012, 46, 4149−4158). The glass transition temperature is below 450 degrees (Summary of the Invention). Quinn teaches phosphate containing materials which comprise zinc (phosphate based glass target materials) (Abstract; Detailed description of the invention). The glass may be in the form of a particle (column 9, left column, first full paragraph). The Quinn fails to teach incorporation of Zn68 into its glass particle. Quinn also fails to tech the present glass transition temperature, the presently claimed density, and the presently claimed isotopic enrichment. Larner teaches that using the relatively inexpensive 68Zn for labeling provides the ability to trace particles (abstract; results and discussion). It would have been obvious to one of ordinary skill in the art at the time the invention was fuled to add Zn68 into the composition of Larner. The motivation for this would be to have the ability to trace the particle. It would have been obvious to optimize the glass transition temperature of the composition, and in this way, would find the presently claimed range. The art provides sufficient guidance to this end, as the range taught by Quinn of less than 450 degrees C overlaps with the present range of 200 to 2000 degrees C. It would have been further obvious to optimize the isotopic enrichment of Zn68 for the purpose of tracing the glass particle. In this way, the artisan would have found the present value through routine experimentation. “‘[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.’ In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)” MPEP § 2144.05, II. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL W DICKINSON whose telephone number is (571)270-3499. The examiner can normally be reached on M-F 9 AM to 7:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL W DICKINSON/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Apr 26, 2023
Application Filed
Aug 11, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734255
RADIOPAQUE POLYMERS WITH ENHANCED RADIOPACITY
7y 4m to grant Granted Sep 15, 2026
Patent 12734257
TERAGNOSTIC METHOD FOR CANCER PATIENTS
2y 0m to grant Granted Sep 15, 2026
Patent 12708606
LITHIUM FLUORIDE NANOPARTICLES FOR THE PROTECTION OF CHONDROCYTES IN OSTEOARTHRITIS
3y 4m to grant Granted Aug 18, 2026
Patent 12673926
NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING
5y 1m to grant Granted Jul 07, 2026
Patent 12649001
COMPLEXES FOR DELIVERY OF ANTIGENIC PEPTIDES
3y 2m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
73%
With Interview (+9.5%)
3y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1047 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month